| Literature DB >> 35135995 |
Frederik Schlitt1, Katharina Schmidt1, Christian J Merz2, Oliver T Wolf2, Julian Kleine-Borgmann1, Sigrid Elsenbruch1,3, Katja Wiech4, Katarina Forkmann1, Ulrike Bingel1.
Abstract
ABSTRACT: Pain-related learning mechanisms likely play a key role in the development and maintenance of chronic pain. Previous smaller-scale studies have suggested impaired pain-related learning in patients with chronic pain, but results are mixed, and chronic back pain (CBP) particularly has been poorly studied. In a differential conditioning paradigm with painful heat as unconditioned stimuli, we examined pain-related acquisition and extinction learning in 62 patients with CBP and 61 pain-free healthy male and female volunteers using valence and contingency ratings and skin conductance responses. Valence ratings indicate significantly reduced threat and safety learning in patients with CBP, whereas no significant differences were observed in contingency awareness and physiological responding. Moreover, threat learning in this group was more impaired the longer patients had been in pain. State anxiety was linked to increased safety learning in healthy volunteers but enhanced threat learning in the patient group. Our findings corroborate previous evidence of altered pain-related threat and safety learning in patients with chronic pain. Longitudinal studies exploring pain-related learning in (sub)acute and chronic pain are needed to further unravel the role of aberrant pain-related learning in the development and maintenance of chronic pain.Entities:
Mesh:
Year: 2021 PMID: 35135995 PMCID: PMC9341232 DOI: 10.1097/j.pain.0000000000002544
Source DB: PubMed Journal: Pain ISSN: 0304-3959 Impact factor: 7.926
Demographic information and patient characteristics.
| CBP group (N = 62) | HC group (N = 61) | |
|---|---|---|
| Demographic data | ||
| Age in years, M ± SD [range] | 34.6 ± 13.4 [16–69] | 33.8 ± 11.8 [19–70] |
| Sex | ||
| Female/male, n (%) | 44/18 (71.0/29.0) | 40/21 (65.6/34.4) |
| Education, n (%) | ||
| Basic (≤10 years) | 12 (19.4) | 7 (11.5) |
| High school (13 years) | 29 (46.7) | 40 (65.5) |
| University (>13 years) | 21 (33.9) | 14 (23.0) |
| Pain-related data, M ± SD [range] | ||
| Pain duration in years | 9.79 ± 8.73 [1–38] | — |
| Mean back pain intensity (last 4 weeks), 1–10 NRS | 4.99 ± 1.56 [2–8] | — |
| Maximum back pain intensity (last 4 weeks), 1–10 NRS | 7.48 ± 1.22 [5–10] | — |
| Current back pain intensity on study day, 1–10 NRS | 3.38 ± 1.98 [0–8] | — |
| Pain severity | ||
| Grade I (low pain intensity and disability) | 23 (37.1) | — |
| Grade II (high pain intensity, low disability) | 27 (43.5) | — |
| Grade III (high pain intensity and disability, moderately limiting) | 8 (12.9) | — |
| Grade IV (high pain intensity and disability, severely limiting) | 4 (6.4) | — |
| Type of medication, n (%) | ||
| Antidepressants | 2 (3.2) | — |
| Nonopioid analgesics | 1 (1.6) | 1 (1.6) |
| Pregabalin | 1 (1.6) | — |
| Others | 10 (16.1) | 10 (16.4) |
Pain grading according to Von Korff et al., 1992.
Daily dose: ASS 100 mg.
Other medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antipsychotics, antihistamines, antidiabetic medication, levothyroxine, HIV medication, asthma medication, bronchodilators, statins, COX-2 inhibitors, proton pump inhibitors, angiotensin-converting-enzyme (ACE) inhibitors, beta-blockers, angiotensin II type 1 (AT1) receptor antagonists, and calcium channel blockers. None of the patients with CBP took benzodiazepines, NSAID, or opioids (>100 mg of morphine equivalent/day according to our inclusion criteria).
CBP, chronic back pain; HC, healthy control; NRS, numeric rating scale.
Figure 1.Differential conditioning paradigm. The experimental paradigm consisted of 3 experimental phases, ie, habituation phase, acquisition training, and extinction training. Assignment of the geometrical figures to experimental conditions was randomized (example shown here). Habituation phase: 6 CS, no US, valence ratings for each CS. Acquisition training: 32 CS, 12 US. Valence (CS+/CS−) and pain intensity ratings (US) after each fourth CS+/CS−/US. Extinction training: 24 CS, no US. Valence ratings (CS+/CS−) after each fourth CS+/CS−. Each CS was displayed for 9 seconds; US presentation was set to 2.5 seconds; CS+-US overlap was set to 1 second. VAS was displayed for 7.5 seconds (valence rating, pain intensity rating) or 15 seconds (contingency rating). Intertrial interval was jittered between 6 and 11 seconds. CS, conditioned stimuli; US, unconditioned stimuli.
Group differences in heat pain–related data, fear and arousal ratings, and self-report questionnaires.
| CBP group (M ± SD) | HC group (M ± SD) | Statistics |
| |
|---|---|---|---|---|
| Heat pain–related data | ||||
| Heat pain thresholds (°C) | 43.8 ± 2.46 | 43.8 ± 1.63 | W = 1809.50 | 0.68 |
| Temperature US (°C) | 47.5 ± 1.84 | 47.7 ± 1.48 | W = 2020.00 | 0.52 |
| Pain intensity rating during acquisition training (0-100 VAS) | 62.5 ± 12.8 | 64.4 ± 10.4 | t(121) = 0.91 | 0.37 |
| Fear and arousal ratings | ||||
| Pain-related fear (0-100 VAS) | 25.2 ± 23.1 | 19.1 ± 15.4 | W = 1225.50 | 0.41 |
| Arousal (0-100 VAS) | 31.0 ± 21.4 | 23.8 ± 19.6 | W = 632.50 | 0.08 |
| Questionnaire data | ||||
| STADI | ||||
| State anxiety | 18.00 ± 5.48 | 15.20 ± 3.02 | W = 1318.50 |
|
| State depression | 18.10 ± 4.51 | 15.80 ± 2.88 | W = 1203.00 |
|
| Trait anxiety | 21.20 ± 6.19 | 17.00 ± 4.37 | W = 1097.50 |
|
| Trait depression | 17.80 ± 4.29 | 15.50 ± 3.23 | W = 1255.50 |
|
| CES-D | 9.68 ± 6.85 | 6.22 ± 5.28 | W = 1265.00 |
|
| PCS | 20.40 ± 9.16 | 11.80 ± 10.10 | W = 971.50 |
|
| PASS 20-D | 31.90 ± 12.40 | 26.30 ± 14.40 | t(120) = −2.30 |
|
| DASS | ||||
| Depression | 3.97 ± 3.85 | 1.30 ± 1.60 | W = 947.00 |
|
| Anxiety | 3.39 ± 3.07 | 1.11 ± 1.39 | W = 970.00 |
|
| Stress | 7.15 ± 4.65 | 2.26 ± 2.59 | W = 619.50 |
|
| TICS | 20.90 ± 8.89 | 16.00 ± 7.71 | t(120) = −3.23 |
|
| PSQ20 | 55.5 ± 18.9 | 43.9 ± 17.2 | t(120) = −3.57 |
|
| FEDA | 100.00 ± 13.10 | 107.00 ± 10.00 | W = 2384.00 |
|
Note that questionnaire data (except for DASS) of 1 HC is missing due to technical problems. Bold entries indicate significant p-values (p<0.05).
Nine patients with CBP (14.5%) scored above the cutoff of 16.
Four patients with CBP (6.5%) scored above the cutoff of 10.
Eleven patients with CBP (17.7%) scored above the cutoff of 6.
Forteen patients with CBP (22.6%) scored above the cutoff of 10.
CBP, chronic back pain; HC, healthy control; CES-D, Center for Epidemiologic Studies Depression Scale; DASS, Depression Anxiety Stress Scales; FEDA, Questionnaire for Experiences of Attention Deficits; PASS 20-D, Pain Anxiety Symptom Scale; PCS, Pain Catastrophizing Scale; PSQ20, Perceived Stress Questionnaire; STADI, State-Trait-Anxiety-Depression-Inventory; TICS, Trier Inventory of Chronic Stress; US, unconditioned stimuli.
Figure 2.Reduced pain-related threat and safety learning (acquisition) in patients with chronic back pain compared with pain-free healthy volunteers: The mean valence ratings (±SEM) of patients with nonspecific chronic back pain (CBP, orange) and healthy volunteers (HCs, blue) for CS− (empty circles) and CS+ (filled circles) during the habituation phase (Hab), acquisition training (Acq 1–Acq 4), and extinction training (Ext 1–Ext 3). Experimental phases are separated by dashed lines. Note that positive CS valence is indexed by negative VAS ratings, and negative CS valence is indexed by positive VAS ratings. CBP, chronic back pain; CS, conditioned stimuli; HC, healthy control.
Figure 3.Comparable contingency awareness in patients with chronic back pain and healthy volunteers. The mean contingency ratings (with SEM) of patients with nonspecific chronic back pain (CBP, orange) and healthy participants (HCs, blue) provided for CS+ (filled circles) and CS− (empty circles) after acquisition (Acq) and extinction training (Ext). CBP, chronic back pain; CS, conditioned stimuli; HC, healthy control.